⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EWTX News
Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
prnewswire.com
EWTX
Form 8-K
sec.gov
EWTX
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
prnewswire.com
EWTX
Form 8-K/A
sec.gov
EWTX
Form 8-K
sec.gov
EWTX
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
prnewswire.com
EWTX